CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model
Background and purpose:
Accumulating recent evidence suggests that cannabinoid-1 (CB1) receptor activation may promote inflammation and cell death and its pharmacological inhibition is associated with anti-inflammatory and tissue-protective effects in various preclinical disease models, as well as in humans.
In this study, using molecular biology and biochemistry methods, we have investigated the effects of genetic deletion or pharmacological inhibition of CB1 receptors on inflammation, oxidative/nitrosative stress and cell death pathways associated with a clinically relevant model of nephropathy, induced by an important chemotherapeutic drug cisplatin.
Cisplatin significantly increased endocannabinoid anandamide content, activation of p38 and JNK mitogen-activated protein kinases (MAPKs), apoptotic and poly (ADP-ribose)polymerase-dependent cell death, enhanced inflammation (leucocyte infiltration, tumour necrosis factor-α and interleukin-1β) and promoted oxidative/nitrosative stress [increased expressions of superoxide-generating enzymes (NOX2(gp91phox), NOX4), inducible nitric oxide synthase and tissue 4-hydroxynonenal and nitrotyrosine levels] in the kidneys of mice, accompanied by marked histopathological damage and impaired renal function (elevated creatinine and serum blood urea nitrogen) 3 days following its administration. Both genetic deletion and pharmacological inhibition of CB1 receptors with AM281 or SR141716 markedly attenuated the cisplatin-induced renal dysfunction and interrelated oxidative/nitrosative stress, p38 and JNK MAPK activation, cell death and inflammatory response in the kidney.
Conclusions and implications:
The endocannabinoid system through CB1 receptors promotes cisplatin-induced tissue injury by amplifying MAPK activation, cell death and interrelated inflammation and oxidative/nitrosative stress. These results also suggest that inhibition of CB1 receptors may exert beneficial effects in renal (and most likely other) diseases associated with enhanced inflammation, oxidative/nitrosative stress and cell death.
This article is part of a themed issue on Cannabinoids. To view the editorial for this themed issue visit http://dx.doi.org/10.1111/j.1476-5381.2010.00831.x
Cisplatin is a potent and widely used chemotherapy drug (a platinum compound) for the treatment of a range of solid tumours and other malignancies (Ries and Klastersky, 1986;Schrier, 2002). Even though the precise mechanism of the anticancer activity of cisplatin is not completely understood, it is widely held that it binds to DNA, leading to the formation of inter- and intrastrand cross-links, resulting in defective DNA templates and arrest of DNA synthesis and replication, particularly in rapidly dividing cancer cells (Wang and Lippard, 2005). Unfortunately, the major limitation of its clinical application is the development of dose-dependent nephrotoxicity in about one-third of patients. This prevents the use of high doses to take full advantage of the therapeutic efficacy (Ries and Klastersky, 1986; Schrier, 2002). Regrettably, efficient treatment to decrease this devastating complication of cisplatin chemotherapy is not available.
The mechanism of cisplatin-induced nephrotoxicity is complex and involves numerous interconnected processes (Pabla and Dong, 2008), such as formation of reactive oxygen (Matsushima et al., 1998; Davis et al., 2001) and nitrogen species (ROS and RNS) (Chirino et al., 2004; 2008;), DNA damage (Ries and Klastersky, 1986) and activation of apoptotic and poly (ADP-ribose) polymerase (PARP)-dependent cell death pathways (Ries and Klastersky, 1986; Racz et al., 2002; Mukhopadhyay et al., 2010a;Pan et al., 2009a). Numerous recent studies highlight the importance of inflammatory mechanisms in the pathogenesis and progression of cisplatin-induced nephropathy, particularly the recruitment of inflammatory cells (e.g. leucocytes and macrophages), which may amplify the drug-induced tubular injury by further increasing ROS and RNS generation and production of a variety of pro-inflammatory mediators [e.g. cytokines: tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-1β)], eventually leading to activation of cell death pathways (Ramesh and Reeves, 2002;Yamate et al., 2002; Faubel et al., 2007; Zhang et al., 2007;Mukhopadhyay et al., 2010a).
Cannabinoid-1 (CB1) receptor antagonists exert potent anti-inflammatory and cytoprotective effects in multiple preclinical disease models ranging from hepatic steatosis (Gary-bobo et al., 2007), ischaemia–reperfusion injury (Berger et al., 2004; Muthianet al., 2004; Sommer et al., 2006; Lim et al., 2009; Zhang et al., 2009), to endotoxin shock (Kadoi and Goto, 2006;Villanueva et al., 2009), atherosclerosis (Pacher and Hasko, 2008;Dol-gleizes et al., 2009; Pacher, 2009; Sugamura et al., 2009), cardiomyopathy (Mukhopadhyay et al., 2007; 2010b;, Pacher et al., 2008) and in in vitro models of inflammation (Malfitano et al., 2008; Schafer et al., 2008; Han et al., 2009). More importantly, rimonabant (SR141716) also attenuates multiple inflammatory markers (e.g. TNF-α, C-reactive protein, etc.), plasma leptin and insulin levels, and increases plasma adiponectin in obese patients with metabolic syndrome and/or type 2 diabetes (reviewed in Di Marzo, 2008;Engeli, 2008;Mach et al., 2008; Pertwee, 2009). Furthermore, a functional endocannabinoid system was reported in the kidney (Deutsch et al., 1997; Janiak et al., 2007), and blockade of cannabinoid CB1 receptors improved renal function, metabolic profile and increased survival of obese Zucker rats (Janiak et al., 2007).
In this study we investigated the interplay of the CB1 receptors with oxidative/nitrosative stress, inflammation and cell death pathways using a well-established mouse model of cisplatin-induced nephropathy. These results may have important implications not only for the prevention of the cisplatin-induced nephrotoxicity, but also for the therapy of other kidney diseases.
Animals and drug treatment
All animal experiments conformed to National Institutes of Health (NIH) guidelines and were approved by the Institutional Animal Care and Use Committee of the National Institute on Alcohol Abuse and Alcoholism (NIAAA; Bethesda, MD, USA). Six- to 8-week-old male C57BL/6J mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). CB1 knockout mice (CB1−/−) and their wild-type littermates (CB1+/+) were as described previously (Osei-Hyiaman et al., 2005) and had been backcrossed to a C57BL/6J background. All animals were kept in a temperature-controlled environment with a 12 h light–dark cycle and were allowed free access to food and water at all times, and were cared for in accordance with National Institutes of Health (NIH) guidelines. Mice were killed 72 h following a single injection of cisplatin (cisdiammineplatinum(II) dichloride 25 mg·kg−1 i.p.; Sigma, St. Louis, MO, USA). The selective CB1 receptor antagonist SR141716 (obtained from NIDA) or AM281 (Tocris, Ellisville, MI, USA) were dissolved as described previously (Mukhopadhyay et al., 2007), and administered at 10 mg·kg−1, i.p. daily, starting 2 h before the cisplatin administration. The drug/molecular target nomenclature (e.g. receptors, ion channels and so on) conforms to BJP‘s Guide to Receptors and Channels (Alexander et al., 2008).
Renal function monitoring
Once the animals had been killed, blood was immediately collected, and serum levels of creatinine and blood urea nitrogen (BUN) were measured using kits from Drew Scientific and a Prochem-V chemical analyser (TX, USA).
Western blot analysis
Antibodies for phosho-p38 mitogen-activated protein kinase (MAPK), total p38 MAPK, phospho-JNK and total JNK were obtained from Cell Signaling Technology (Danvers, MA, USA). Antibodies for β-actin were obtained from Cayman (Ann Arbor, MI, USA). Antibodies for CB1 were as previously described (Mukhopadhyay et al., 2007; 2010b;). The kidney protein samples were mixed in Laemmli loading buffer, boiled for 8 min, and then subjected to SDS-PAGE. After electrophoresis, proteins were transferred onto nitrocellulose membranes and blotted against primary antibody (1:1000 dilution) for 16 h. Membranes were washed with PBS-T and incubated with a secondary antibody (1:1000 dilution) for 2 h. Protein bands were visualized by chemiluminescence reaction using SuperSignal West Pico Substrate (Fisher Scientific, Pittsburgh, PA, USA).
For measuring endocannabinoid levels, mice were killed and their kidneys were removed and extracted. Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) levels were determined by liquid chromatography/mass spectrometry from kidney tissues (Batkai et al., 2007). Values are expressed as fmol or pmol·mg−1 wet tissue.
Following fixation of the kidneys with 10% formalin, renal tissues were sectioned and stained with periodic acid-Schiff (PAS) reagents for histological examination. Tubular damage in PAS-stained sections was examined under the microscope (200× magnification) and scored based on the percentage of cortical tubules showing epithelial necrosis: 0 = normal; 1 ≤ 10%; 2 = 10–25%; 3 = 26–75%; 4 ≥ 75%. Tubular necrosis was defined as the loss of the proximal tubular brush border, blebbing of apical membranes, tubular epithelial cell detachment from the basement membrane or intraluminal aggregation of cells and proteins as described (Mukhopadhyay et al., 2010a; Pan et al., 2009a,b;). The morphometric examination was performed in a blinded manner by two independent investigators.
Detection of apoptosis by terminal deoxynucleotidyl transferase-mediated uridine triphosphate (dUTP) nick-end labelling (TUNEL), renal DNA fragmentation and caspase-3/7 activity assays
Apoptosis was assessed by TUNEL, and the number of apoptotic cells, as defined by chromatin condensation or nuclear fragmentation (apoptotic bodies), was counted. Apoptosis was detected in the kidneys by TUNEL assay according to the instructions of the manufacturer of the kit (Roche Diagnostics, Indianapolis, IN, USA) as described previously (Mukhopadhyay et al., 2010a). The morphometric examination was performed by two independent, blinded investigators. The number of apoptotic cells in each section was calculated by counting the number of TUNEL-positive apoptotic cells in 10, 200× fields per slide (Mukhopadhyayet al., 2010a).
Caspase-3/7 activity of the lysate was measured using Apo-One Homogenous caspase-3/7 Assay Kit (Promega Corp., Madison, WI, USA). An aliquot of caspase reagent was added to each well, mixed on a plate shaker for 1 h at room temperature with light protection, and the fluorescence was measured.
The DNA fragmentation assay is based on measuring the amount of mono- and oligonucleosomes in the cytoplasmic fraction of tissue extracts using a commercially available kit (Roche, GmbH) according to manufacturer’s instructions, as described previously (Pan et al., 2009a; Mukhopadhyay et al., 2009).
Renal PARP activity and nitrotyrosine (NT) content
Poly (ADP-ribose) polymerase activity was determined by an assay kit according to manufacturer’s instructions (Trevigen, Gaithersburg, MD, USA) (Pan et al., 2009a; Mukhopadhyay et al., 2009). NT was measured by the NT elisa kit from Hycult Biotechnology (Cell Sciences, Canton, MA, USA) from tissue homogenates as described previously (Mukhopadhyay et al., 2009). Levels were presented as fold change compared with vehicle-treated control sample.
Renal myeloperoxidase activity assay
Myeloperoxidase (EC220.127.116.11) was measured by an InnoZyme™ Myeloperoxidase Activity Kit (EMD, Gibbstown, NJ, USA) according to manufacturer’s instruction. Myeloperoxidase activities were expressed as fold change compared with the vehicle-treated control sample (Mukhopadhyay et al., 2010a).
Renal 4-hydroxynonenal (4-HNE) content
4-HNE in the kidney tissues was determined using the kit (Cell Biolabs, San Diego, CA, USA). In brief, BSA or myocardial tissue extracts (10 µg·mL−1) were adsorbed on to a 96-well plate for 12 h at 4°C. 4-HNE adducts present in the sample or standard were probed with anti-HNE antibody, followed by an horseradish peroxidase-conjugated secondary antibody. The HNE protein adducts content in an unknown sample was determined by comparing with a standard curve as described previously (Mukhopadhyay et al., 2010a).
Real-time PCR analyses
Total RNA was isolated from kidney homogenate using Trizol reagents (Invitrogen, Carlsbad, CA, USA) according to manufacturer’s instruction. The isolated RNA was treated with RNase-free DNase (Ambion, Austin, TX, USA) to remove traces of genomic DNA contamination. One microgram of total RNA was reverse-transcribed to cDNA using the Super-Script II (Invitrogen). The target gene expression was quantified with Power Syber Green PCR Master Mix using ABI 7500 Realtime PCR Instrument. Each amplified sample in all wells was analysed for homogeneity using dissociation curve analysis. After denaturation at 95°C for 2 min, 40 cycles were performed at 95°C for 10 s, 60°C for 30 s. Relative quantification was calculated using the comparative CT method [2-Ct method: Ct = Ct sample − Ct (Mukhopadhyay et al., 2010a,b;)]. Lower CT values and lower CT reflect a relatively higher amount of gene transcript. Statistical analyses were carried out for at least 6–15 replicate experimental samples in each set.
- TNF-α: 5′-AAGCCTGTAGCCCACGTCGTA-3′ and 5′-AGGTACAACCCATCGGCTGG-3′
- IL-1β: 5′-AAAAAAGCCTCGTGCTGTCG-3′ and 5′-GTCGTTGCTTGGTTCTCCTTG-3′
Inducible nitric oxide synthase (iNOS): 5′-ATTCACAGCTCATCCGGTACG-3′ and 5′-GGATCTTGACCATCAGCTTGC-3′
- gp91phox: 5′-GACCATTGCAAGTGAACACCC-3′ and 5′-AAATGAAGTGGACTCCACGCG-3′
- NOX4: 5′-TCATTTGGCTGTCCCTAAACG-3′ and 5′-AAGGATGAGGCTGCAGTTGAG-3′
- Actin: 5′-TGCACCACCAACTGCTTAG-3′ and 5′-GGATGCAGGGATGATGTTC-3′.
Results are reported as mean ± SEM. Statistical significance between two measurements was determined by Student’s two-tailed unpaired t-test (and among groups it was determined by anovafollowed by post hoc Student-Newman-Keuls) by using GraphPad Prism 4.3 software (San Diego, CA, USA). Probability values of P< 0.05 were considered significant.
CB1 receptors were expressed in the kidneys and cisplatin increased endocannabinoid AEA levels
CB1 receptors were expressed in the normal kidneys, and their levels were not altered by cisplatin or by the treatments indicated (Figure 1A,B). Endocannabinoids AEA and 2-AG were detectable in the kidneys of mice, and cisplatin increased tissue levels of AEA but not 2-AG (Figure 1C).
Pharmacological inhibition or genetic deletion of CB1 receptors attenuates the cisplatin-induced renal dysfunction in mice
Levels of BUN and creatinine were measured at 72 h after cisplatin or vehicle administration in the serum of either SR141716- or AM281-treated and untreated mice or in CB1−/− or CB1+/+ mice treated with cisplatin or vehicle. As shown in Figure 2, cisplatin administration induced severe renal dysfunction, which was attenuated by CB1 antagonists AM281 and SR141716 (Figure 2A) or in CB1−/− mice (Figure 2B) compared with CB1+/+ littermates. AM281/SR141716 alone had no effects on BUN and creatinine levels as compared with the vehicle-treated group.
Pharmacological inhibition or genetic deletion of CB1 receptors attenuated the cisplatin-induced histopathological damage in murine kidneys
Cisplatin induced profound histopathological renal injury 72 h after its administration to mice as evidenced by protein casts, vacuolation and desquamation of epithelial cells in the renal tubules using PAS staining (Figure 3). These histopathological changes were attenuated by treatment with AM281 or SR141716 (Figure 3A). Likewise less damage was seen in CB1−/−mice compared with CB1+/+ littermates (Figure 3B).
Pharmacological inhibition or genetic deletion of CB1 receptors attenuated the cisplatin-induced cell death in murine kidneys
Cell death in the kidneys was evaluated by caspase-3/7 activity, DNA fragmentation, TUNEL and PARP activity assays. Cisplatin increased all markers of cell death in the kidneys, which were attenuated by treatment with AM281 or SR141716 (Figure 4A). Likewise, kidneys of cisplatin-treated CB1−/− mice showed considerably less cell death compared with those from their CB1+/+littermates (Figure 4B).
Pharmacological inhibition or genetic deletion of CB1 receptors attenuated the cisplatin-induced increased leucocyte infiltration and inflammatory response in murine kidneys
Cisplatin significantly increased renal myeloperoxidase activity (Figure 5A,B; an indicator of leucocyte infiltration) and expression of TNF-α and IL-1β mRNA (Figure 5C,D), indicating an enhanced inflammatory response. All of these markers of inflammation were attenuated by AM281 or SR141716 treatment (Figure 5A,C), as well as by genetic deletion of CB1 receptors (Figure 5B,D).
Pharmacological inhibition or genetic deletion of CB1 receptors attenuated markers of cisplatin-induced increased oxidative/nitrosative stress
Cisplatin induced significant elevations of renal 4-HNE and NT levels (markers of oxidative and nitrosative damage), which were attenuated by AM281 or SR141716 treatment (Figure 6A,C). Likewise, in CB1−/− mice the markers of oxidative/nitrosative stress were attenuated compared with CB1+/+ littermates (Figure 6B,C). Interestingly, NT was localized in damaged renal tubular cells in cisplatin-treated mice (Figure 6C) supporting the important role of peroxynitrite in cell death processes (Liaudet et al., 2009; Mukhopadhyay et al., 2010a). NT was undetectable in kidneys of normal mice by immunohistochemistry (Figure 6C).
Pharmacological inhibition or genetic deletion of CB1 receptors attenuated the cisplatin-induced increased expression of ROS-generating NADPH oxidase enzymes [NOX4(RENOX), NOX2(gp91phox)] and the iNOS
Cisplatin induced marked increases in mRNA levels of renal NOX4, NOX2 and iNOS 72 h after its administration to mice (Figure 7). These increases were attenuated by AM281 or SR141716 treatment (Figure 7A,C). Similarly, in CB1−/− mice the increase in the mRNA expression for these enzymes was reduced compared with CB1+/+ littermates (Figure 7B,D).
Pharmacological inhibition or genetic deletion of CB1 receptors attenuated the cisplatin-induced increased activation of p38 and JNK MAPKs
Cisplatin induced marked phosphorylation of renal p38 MAPK and JNK 72 h following its administration to mice. The CB1antagonists AM281 or SR141716 (Figure 8A) significantly attenuated these increases. Likewise these increases were reduced in CB1−/− mice compared with their CB1+/+ littermates (Figure 8B).
In this study, we have explored the interplay of oxidative/nitrosative stress, inflammation and cell death pathways with CB1 receptors in a clinically relevant model of cisplatin-induced nephropathy by using pharmacological antagonists of the cannabinoid CB1 receptor (AM281 and SR141716) as well as CB1receptor knockout mice. We demonstrated that genetic deletion of CB1 receptors or its pharmacological inhibition with AM281 or SR141716 attenuates cisplatin-induced increased p38 and JNK MAPK activation, oxidative/nitrosative stress, cell death and interrelated inflammatory cell infiltration in the kidney, and the consequent release of reactive oxidants and pro-inflammatory mediators, leading to decreased cell death of renal tubular cells and marked improvement in cisplatin-induced compromised renal function. These findings suggest that CB1 cannabinoid receptor activation by endocannabinoids promotes cisplatin-induced tissue injury by amplifying MAPK activation, cell death and the associated inflammation and oxidative/nitrosative stress. Therefore, CB1 inhibition may exert beneficial effects in kidney (and most likely other) diseases associated with inflammation, oxidative/nitrosative stress and cell death. These findings are in good agreement with numerous recent reports demonstrating anti-inflammatory and cytoprotective effects of CB1 antagonists in various preclinical disease models, as well as in humans with metabolic syndrome as described above (Pacher et al., 2006; Di Marzo, 2008; Engeli, 2008; Mach et al., 2008; Pertwee, 2009).
There is increasing recognition that in various pathological conditions CB1 receptor activation by endocannabinoids may promote activation of signalling pathways (e.g. p38 and JNK MAPKs) leading to cell death (Pertwee, 2002; Di Marzo, 2008;Dalton et al., 2009). Indeed increased tissue and/or serum endocannabinoid levels during reperfusion injury positively correlate with tissue damage and cell death in experimental models of hepatic ischaemia–reperfusion (Batkai et al., 2007; Pacher and Gao, 2008; Pacher and Hasko, 2008; Ishii et al., 2009) and stroke (Berger et al., 2004; Muthian et al., 2004; Sommer et al., 2006;Zhang et al., 2009). Under many of these experimental conditions CB2 receptor activation on inflammatory, endothelial and perhaps some parenchymal cells exerts anti-inflammatory and cytoprotective effects (Batkai et al., 2007; Rajesh et al., 2007a,b;), while CB1 activation may promote inflammation and tissue injury. Support for this comes from the observation that in these models CB1 antagonists consistently exert beneficial effects on inflammation and the subsequent oxidative/nitrosative stress-cell death cascade (Pacher and Hasko, 2008; Caraceni et al., 2009;Zhang et al., 2009). One can envisage that the overactivated endocannabinoid system during reperfusion, and most likely in other forms of tissue injury [as we describe in the case of cisplatin-induced nephropathy and have recently demonstrated in doxorubicin-induced cardiomyopathy models (Mukhopadhyay et al., 2010b)] may promote cell death through the activation of CB1receptors in certain cell types, and the consequent inflammatory cell infiltration and oxidative stress, while it may serve as an endogenous mechanism to limit early inflammatory response through the activation of CB2 receptors (Pacher and Hasko, 2008). Therefore, the beneficial or detrimental effects of endocannabinoids may largely depend on the tissue and injury type (e.g. role of the inflammatory component for example, expression of CB1/2 receptors, etc.), as well as on the stage of the disease progression. Indeed, CB2 receptor activation limits inflammation and interrelated oxidative/nitrosative stress-cell death associated with cisplatin-induced nephropathy. However, the protective effect of a CB2 agonist is lost when it is administered after the development of the initial inflammatory response (Mukhopadhyayet al., 2010a). Other examples of such opposing regulation of inflammatory and/or fibrotic pathways by CB1/2 cannabinoid receptors are atherosclerosis (Mach et al., 2008; Pacher and Steffens, 2009) and liver fibrosis (Julien et al., 2005; Teixeira-clercet al., 2006; Lotersz
tajn et al., 2008), where CB2 activation (Steffens et al., 2005) and/or CB1 inactivation (Dol-gleizes et al., 2009; Sugamura et al., 2009) appears to limit vascular inflammation and/or fibrosis and interrelated disease progression. In clinical trials the CB1 antagonist/inverse agonist rimonabant (SR141716) also attenuated multiple inflammatory markers (e.g. TNF-α, C-reactive protein, etc.), plasma leptin and insulin levels and increased plasma adiponectin in obese patients with metabolic syndrome and/or type 2 diabetes (Engeli, 2008; Pacher et al., 2008;Pacher and Steffens, 2009). Furthermore, chronic rimonabant treatment restores plasma levels of the anti-inflammatory hormone adiponectin, reduces the elevated plasma/serum levels of TNF-α (Gary-bobo et al., 2007), reduces RANTES (regulated on activation, normal T cell expressed and secreted) and MCP-1(Schafer et al., 2008) in obese Zucker fa/fa rats and decreases NF-κB activation and consequent iNOS expression in mitogen-stimulated human peripheral blood mononuclear cells (Malfitano et al., 2008). In the context of cisplatin-induced nephrotoxicity, the above-mentioned effect of rimonabant on TNF-α, NF-κB activation and increased expression on iNOS in stimulated human peripheral blood mononuclear cells and on LPS-stimulated macrophage inflammatory responses may be particularly relevant, as pro-inflammatory cytokines such as TNF-α and iNOS-derived oxidative/nitrosative stress are crucial mediators in the pathogenesis of cisplatin-induced kidney injury (Ramesh and Reeves, 2002; Zhang et al., 2007; Chirino et al., 2008).
Indeed, cisplatin-induced oxidative (Matsushima et al., 1998; Daviset al., 2001) and nitrosative (Chirino et al., 2004; 2008😉 stress, subsequent inflammation (Yamate et al., 2002; Faubel et al., 2007) and the associated activation of various cell death pathways [e.g. p38 JNK MAPKs, PARP (Racz et al., 2002)] play an important role in the pathogenesis of renal dysfunction. The most likely sources of increased ROS generation by cisplatin in the kidney, in particular superoxide, are the superoxide-generating enzymes NAD(P)H oxidase NOX4(RENOX) and phagocyte NAD(P)H oxidase (NOX2) (Mukhopadhyay et al., 2010a; Pan et al., 2009a). It is well known that inflammatory cells upon activation produce a plethora of various ROS and RNS [e.g. superoxide, iNOS-derived nitric oxide (NO) and consequently peroxynitrite via diffusion-limited reaction of superoxide with NO], which contribute to tissue injury via complex interrelated mechanisms comprising of increased lipid peroxidation, changes in pro-inflammatory gene expressions in both inflammatory and parenchymal cells, secretion of pro-inflammatory mediators (e.g. cytokines, chemokines), oxidation/nitration of key regulatory proteins involved in cell metabolism, signalling processes implicated in proliferation, survival and/or death, eventually leading to the activation of various mitochondrial-dependent or independent cell death pathways culminating in organ dysfunction and failure (Pacher et al., 2007; Szabo et al., 2007). Indeed, increasing evidence suggests that the reactive nitrogen species peroxynitrite and/or the consequent protein nitration may be involved in the modulation of various cell survival and death pathways (Liaudet et al., 2009), as well as in certain physiological processes (Ferdinandy, 2006), in addition to promoting tissue injury (Ferdinandy and Schulz, 2003;Pacher et al., 2007). Cisplatin-induced ROS generation might also favour augmented expression of iNOS through the activation of NF-κB, which further increases the generation of NO and RNS amplifying nitrosative stress.
In agreement with previous reports, we found that a single dose of cisplatin induced marked histopathological damage, increased inflammatory cell infiltration and impaired renal function. It also lead to marked up-regulation of TNF-α and IL-1β mRNA in the kidneys, consistent with the important role of TNF-α (Ramesh and Reeves, 2002; Zhang et al., 2007) in cisplatin-induced nephrotoxicity. Interestingly, cisplatin-induced kidney injury largely depends on TNF-α, as TNF-α-deficient mice and TNF-α antibody-treated wild-type mice display resistance to cisplatin-induced kidney toxicity (Ramesh and Reeves, 2002; Zhang et al., 2007). Further supporting the importance of iNOS-derived increased nitrosative stress in cisplatin-induced renal injury (Chirino et al., 2008), we also found significantly increased iNOS expression in the kidneys of cisplatin-treated mice. In fact, nitrosative stress and/or peroxynitrite, and the activation of interconnected effector downstream pathways such as PARP, have importantly been implicated in the development of cisplatin-induced cell demise and subsequent nephropathy (Racz et al., 2002;Chirino et al., 2004; 2008;). This notion is also supported by our current observations that cisplatin treatment increased renal NT formation, DNA fragmentation and PARP activity.
Remarkably, the cisplatin-induced pathological alterations were markedly attenuated by CB1 antagonists or in CB1−/− mice compared with their wild-type littermates. CB1 antagonists AM281 and SR141716 not only attenuated the cisplatin-induced increased inflammatory response (chemokine secretion, inflammatory cell infiltration, TNF-α and IL-1β levels), but also reduced the expression of ROS-generating enzymes, NOX4 and NOX2, and the renal oxidative stress. In agreement with these results, a recent study has elegantly demonstrated a pivotal role of CB1 receptors in the generation of ROS by macrophages (Han et al., 2009). In addition, CB1−/− mice were largely resistant to cisplatin-induced nephropathy, further supporting an important role for the endocannabinoid system and CB1 receptors in the development of the above-mentioned pathological processes and consequent nephropathy. CB1 genetic deletion or pharmacological inhibition was also associated with decreased cisplatin-induced iNOS overexpression and NT formation [the marker of peroxynitrite generation and more broadly nitrosative stress (Pacher et al., 2007)] in the kidneys, and consequent cell death (both apoptotic and necrotic) and renal dysfunction. Genetic deletion of CB1 receptors (Mukhopadhyay et al., 2010b) or pharmacological inhibition (P. Mukhopadhyay and P. Pacher, unpublished) also attenuates the doxorubicin [another chemotherapeutic drug known for its cardiotoxicity (Mukhopadhyay et al., 2009)]-induced increased myocardial oxidative/nitrosative stress and cardiac dysfunction (Mukhopadhyay et al., 2007; 2010b;).
Our results are in good agreement with the emerging anti-inflammatory and cytoprotective effects of CB1 pharmacological inhibition or genetic deletion observed in the numerous preclinical and clinical reports discussed above. These effects may involve attenuation of the inflammatory cell infiltration, TNF-α production, NF-κB activation and consequent increased expression of iNOS in peripheral blood mononuclear cells and/or parenchymal cells, just to name a few. Because increased oxidative/nitrosative stress and inflammation is known to trigger increased endocannabinoid production or impair endocannabinoid inactivation (Di Marzo, 2008; Liu et al., 2008; Pacher and Hasko, 2008), it is likely that endocannabinoids contribute to cisplatin-induced nephrotoxicity by promoting oxidative/nitrosative stress, inflammation and cell death through the activation of CB1 receptors. The enhanced cisplatin-induced p38 and JNK MAPK activation may also be a consequence, at least in part, of the dys-regulated endocannabinoid production, as this signalling pathway (gaining increasing recognition as a part of CB1 receptor activation) is attenuated in CB1−/− mice or in mice treated with CB1 antagonists. In agreement with these results, we have recently demonstrated that CB1receptors promote oxidative/nitrosative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human primary cardiomyocytes through activation of p38 and JNK MAPKs (Mukhopadhyay et al., 2010b).
In summary, the endocannabinoid system through CB1 receptors promotes cisplatin-induced tissue injury by amplifying MAPK activation, cell death and interrelated inflammation and oxidative/nitrosative stress. Thus, pharmacological inhibition of CB1 receptors may exert beneficial effects against cisplatin-induced nephrotoxicity, which is particularly exciting as recent studies have demonstrated multiple beneficial effects of CB1antagonists in various cancer types (Bifulco and Pisanti, 2009;Pisanti and Bifulco, 2009;Santoro et al., 2009) and suggested that endocannabinoid overactivity might be involved in renal complications of human visceral obesity (Bordicchia et al., 2009). These results may also have important implications for the treatment of kidney or other diseases associated with enhanced inflammation, oxidative/nitrosative stress and cell death.
This study was supported by the Intramural Research Program of NIH/NIAAA (to PP) and NIH/NIDA (DA11322 & DA21696 to KM). Authors are indebted to Dr George Kunos for the endocannabinoid measurements. PP dedicates this study to his beloved mother Iren Bolfert, who died from the complications of chemotherapy.
- blood urea nitrogen
- CB1−/− mice
- CB1 knockout mice
- CB1 receptor
- cannabinoid-1 receptor
- inducible nitric oxide synthase
- nitric oxide
- poly (ADP-ribose) polymerase
- reactive oxygen species
- rimonabant, a CB1 antagonist (inverse agonist)
- tumour necrosis factor-α
Conflict of interest
No conflict of interest to disclose.
- Alexander SP, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol.2008;153:S1–209. [PMC free article] [PubMed]
- Batkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, Mukhopadhyay P, et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury.FASEB J. 2007;21:1788–1800. [PMC free article] [PubMed]
- Berger C, Schmid PC, Schabitz WR, Wolf M, Schwab S, Schmid HH. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem. 2004;88:1159–1167. [PubMed]
- Bifulco M, Pisanti S. End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion. Nat Rev Drug Discov.2009;8:594. [PubMed]
- Bordicchia M, Battistoni I, Mancinelli L, Giannini E, Refi G, Minardi D, et al. Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. Metabolism. 2009 doi:10.1016/j.metabol.2009.09.018. [PubMed]
- Caraceni P, Pertosa AM, Giannone F, Domenicali M, Grattagliano I, Principe A, et al. Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia.Gut. 2009;58:1135–1143. [PubMed]
- Chirino YI, Hernandez-Pando R, Pedraza-Chaverri J. Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC Pharmacol. 2004;4:20.[PMC free article] [PubMed]
- Chirino YI, Trujillo J, Sanchez-Gonzalez DJ, Martinez-Martinez CM, Cruz C, Bobadilla NA, et al. Selective iNOS inhibition reduces renal damage induced by cisplatin. Toxicol Lett.2008;176:48–57. [PubMed]
- Dalton GD, Bass CE, Van Horn C, Howlett AC. Signal transduction via cannabinoid receptors. CNS Neurol Disord Drug Targets. 2009;8:422–431. [PMC free article] [PubMed]
- Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol.2001;12:2683–2690. [PubMed]
- Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest. 1997;100:1538–1546. [PMC free article][PubMed]
- Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov. 2008;7:438–455. [PubMed]
- Dol-Gleizes F, Paumelle R, Visentin V, Mares AM, Desitter P, Hennuyer N, et al. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2009;29:12–18. [PubMed]
- Engeli S. Dysregulation of the endocannabinoid system in obesity. J Neuroendocrinol. 2008;20:110–115. [PubMed]
- Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, et al. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther. 2007;322:8–15. [PubMed]
- Ferdinandy P. Peroxynitrite: just an oxidative/nitrosative stressor or a physiological regulator as well? Br J Pharmacol.2006;148:1–3. [PMC free article] [PubMed]
- Ferdinandy P, Schulz R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol. 2003;138:532–543.[PMC free article] [PubMed]
- Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology.2007;46:122–129. [PubMed]
- Han KH, Lim S, Ryu J, Lee CW, Kim Y, Kang JH, et al. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages.Cardiovasc Res. 2009;84:378–386. [PubMed]
- Ishii Y, Sakamoto T, Ito R, Yanaga K. F(2)-isoprostanes and 2-arachidonylglycerol as biomarkers of lipid peroxidation in pigs with hepatic ischemia/reperfusion injury. J Surg Res.2009 in press. [PubMed]
- Janiak P, Poirier B, Bidouard JP, Cadrouvele C, Pierre F, Gouraud L, et al. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int. 2007;72:1345–1357. [PubMed]
- Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology. 2005;128:742–755. [PubMed]
- Kadoi Y, Goto F. Effects of AM281, a cannabinoid antagonist, on circulatory deterioration and cytokine production in an endotoxin shock model: comparison with norepinephrine. J Anest. 2006;20:284–289. [PubMed]
- Liaudet L, Vassalli G, Pacher P. Role of peroxynitrite in the redox regulation of cell signal transduction pathways. Front Biosci. 2009;14:4809–4814. [PMC free article] [PubMed]
- Lim SY, Davidson SM, Yellon DM, Smith CC. The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction. Basic Res Cardiol. 2009;104:781–792.[PubMed]
- Liu J, Wang L, Harvey-White J, Huang BX, Kim HY, Luquet S, et al. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology. 2008;54:1–7.[PMC free article] [PubMed]
- Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, Manin S, et al. CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol. 2008;153:286–289.[PMC free article] [PubMed]
- Mach F, Montecucco F, Steffens S. Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol. 2008;153:290–298. [PMC free article] [PubMed]
- Malfitano AM, Laezza C, Pisanti S, Gazzerro P, Bifulco M. Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells. Br J Pharmacol. 2008;153:1003–1010.[PMC free article] [PubMed]
- Matsushima H, Yonemura K, Ohishi K, Hishida A. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med. 1998;131:518–526. [PubMed]
- Mukhopadhyay P, Batkai S, Rajesh M, Czifra N, Harvey-White J, Hasko G, et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol. 2007;50:528–536.[PMC free article] [PubMed]
- Mukhopadhyay P, Rajesh M, Batkai S, Kashiwaya Y, Hasko G, Liaudet L, et al. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol. 2009;296:H1466–H1483. [PMC free article] [PubMed]
- Mukhopadhyay P, Mohanraj R, Pan H, Patel V, Mukhopadhyay B, Batkai S, et al. Cannabinoid-2 receptor limits inflammation, oxidative-nitrosative stress and cell death in nephropathy. Free Radic Biol Med. 2010a;48:457–467.[PMC free article] [PubMed]
- Mukhopadhyay P, Rajesh M, Batkai S, Patel V, Kashiwaya Y, Liaudet L, et al. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res. 2010b;85:773–784.[PMC free article] [PubMed]
- Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ. Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience. 2004;129:743–750.[PubMed]
- Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115:1298–1305.[PMC free article] [PubMed]
- Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73:994–1007.[PubMed]
- Pacher P. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? Arterioscler Thromb Vasc Biol. 2009;29:7–9.[PMC free article] [PubMed]
- Pacher P, Gao B. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases. Am J Physiol Gastrointest Liver Physiol. 2008;294:G850–G854.[PMC free article] [PubMed]
- Pacher P, Hasko G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol. 2008;153:252–262. [PMC free article] [PubMed]
- Pacher P, Steffens S. The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol.2009;31:63–77. [PMC free article] [PubMed]
- Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev.2006;58:389–462. [PMC free article] [PubMed]
- Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87:315–424.[PMC free article] [PubMed]
- Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Batkai S, Kunos G. Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations.Hypertension. 2008;52:601–607. [PMC free article] [PubMed]
- Pan H, Mukhopadhyay P, Rajesh M, Patel V, Mukhopadhyay B, Gao B, et al. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J Pharmacol Exp Ther.2009a;328:708–714. [PMC free article] [PubMed]
- Pan H, Shen Z, Mukhopadhyay P, Wang H, Pacher P, Qin X, et al. Anaphylatoxin C5a contributes to the pathogenesis of cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol. 2009b;296:F496–F504. [PMC free article] [PubMed]
- Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacol Ther. 2002;95:165–174. [PubMed]
- Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol.2009;156:397–411. [PMC free article] [PubMed]
- Pisanti S, Bifulco M. Endocannabinoid system modulation in cancer biology and therapy. Pharmacol Res. 2009;60:107–116. [PubMed]
- Racz I, Tory K, Gallyas F, Jr, Berente Z, Osz E, Jaszlits L, et al. BGP-15 – a novel poly(ADP-ribose) polymerase inhibitor – protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem Pharmacol.2002;63:1099–1111. [PubMed]
- Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Huffman JW, et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol.2007a;293:H2210–H2218. [PMC free article] [PubMed]
- Rajesh M, Pan H, Mukhopadhyay P, Batkai S, Osei-Hyiaman D, Hasko G, et al. Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol. 2007b;82:1382–1389.[PMC free article] [PubMed]
- Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002;110:835–842.[PMC free article] [PubMed]
- Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity.Am J Kidney Dis. 1986;8:368–379. [PubMed]
- Santoro A, Pisanti S, Grimaldi C, Izzo AA, Borrelli F, Proto MC, et al. Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon. Int J Cancer. 2009;125:996–1003. [PubMed]
- Schafer A, Pfrang J, Neumuller J, Fiedler S, Ertl G, Bauersachs J. The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br J Pharmacol.2008;154:1047–1054. [PMC free article] [PubMed]
- Schrier RW. Cancer therapy and renal injury. J Clin Invest.2002;110:743–745. [PMC free article] [PubMed]
- Sommer C, Schomacher M, Berger C, Kuhnert K, Muller HD, Schwab S, et al. Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra. Acta Neuropathol. 2006;112:277–286. [PubMed]
- Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature. 2005;434:782–786. [PubMed]
- Sugamura K, Sugiyama S, Nozaki T, Matsuzawa Y, Izumiya Y, Miyata K, et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages.Circulation. 2009;119:28–36. [PubMed]
- Szabo C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov. 2007;6:662–680. [PubMed]
- Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.Nat Med. 2006;12:671–676. [PubMed]
- Villanueva A, Yilmaz MS, Millington WR, Cutrera RA, Stouffer DG, Parsons LH, et al. Central cannabinoid-1 receptor antagonist administration prevents endotoxic hypotension affecting norepinephrine release in the preoptic anterior hypothalamic area. Shock. 2009;32:614–620. [PubMed]
- Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4:307–320. [PubMed]
- Yamate J, Sato K, Ide M, Nakanishi M, Kuwamura M, Sakuma S, et al. Participation of different macrophage populations and myofibroblastic cells in chronically developed renal interstitial fibrosis after cisplatin-induced renal injury in rats.Vet Pathol. 2002;39:322–333. [PubMed]
- Zhang B, Ramesh G, Norbury CC, Reeves WB. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int.2007;72:37–44. [PubMed]
- Zhang M, Martin BR, Adler MW, Razdan RJ, Kong W, Ganea D, et al. Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimmune Pharmacol. 2009;4:249–259. [PMC free article] [PubMed]